NCT05691010

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.

Conditions

• Endometrial Cancer
• Stage III Endometrial Cancer
• Stage III Endometrial Carcinoma
• Endometrial Carcinoma
• Endometrial Carcinoma Stage III

Interventions

Type	Name	Description
RADIATION	Intensity-modulated radiation therapy	After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
DRUG	Carboplatin	Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
DRUG	Paclitaxel	Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles

Timeline

• Start date: 2023-01-10
• Primary completion: 2027-01-10
• Completion: 2027-01-10
• First posted: 2023-01-19
• Last updated: 2026-02-04

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study